Lung cancer continues to be one of the leading causes of cancer-related death worldwide. There is evidence of a complex interplay between lung cancer and interstitial lung disease (ILD), affecting disease progression, management strategies, and patient outcomes. Both conditions develop as the result of common risk factors such as smoking, environmental exposures, and genetic predispositions. The presence of ILD poses diagnostic and therapeutic challenges in lung cancer management, including difficulties in interpreting radiological findings and increased susceptibility to treatment-related toxicities, such as acute exacerbation of ILD after surgery and pneumonitis after radiation therapy and immunotherapy. Moreover, due to the lack of large, phase III randomized controlled trials, the evidence-based therapeutic options for patients with ILDs and lung cancer remain limited. Antifibrotic treatment may help prevent pulmonary toxicity due to lung cancer treatment, but its effect is still unclear. Emerging diagnostic modalities and biomarkers and optimizing personalized treatment strategies are essential to improve outcomes in this patient population.
肺癌仍是全球癌症相关死亡的主要原因之一。现有证据表明肺癌与间质性肺病之间存在复杂的相互作用，这种相互作用影响着疾病进展、治疗策略及患者预后。这两种疾病的发展均源于吸烟、环境暴露和遗传易感性等共同风险因素。间质性肺病的存在给肺癌诊疗带来挑战，包括影像学结果解读困难，以及治疗相关毒性风险增加，如术后间质性肺病急性加重、放疗和免疫治疗后肺炎等。此外，由于缺乏大规模III期随机对照试验，针对合并间质性肺病的肺癌患者的循证治疗方案仍十分有限。抗纤维化治疗或有助于预防肺癌治疗引起的肺毒性，但其效果尚不明确。采用新兴诊断方法和生物标志物，并优化个体化治疗策略，对改善此类患者预后至关重要。
肿瘤(癌症)患者之家